At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
IMO-8400 Dose Group 1 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
In Brief
A Phase 2 clinical trial evaluating IMO-8400 Dose Group 1, IMO-8400 Dose Group 2, and 1 other intervention for Dermatomyositis. Completed, enrolled 30 participants across 20 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine how safe and effective IMO-8400 is in adults with dermatomyositis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatomyositis
CountriesHungary, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartNov 2015
First PostedNov 2015
Primary CompletionMay 2018
Study CompletionJun 2018
TodayJul 2026
First PostedNov 24, 2015
Enrollment StartNov 1, 2015
Primary CompletionMay 16, 2018
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.6 years ago
Interventions
IMO-8400 Dose Group 1drug
IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
IMO-8400 Dose Group 2drug
IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
Placebodrug
normal saline subcutaneous injections once a week for 24 weeks.